(KIDS) Orthopediatrics - Ratings and Ratios
Orthopedic, Implants, Instruments, Braces, Trauma, Deformity, Scoliosis
KIDS EPS (Earnings per Share)
KIDS Revenue
Description: KIDS Orthopediatrics
OrthoPediatrics Corp is a medical device company specializing in the design, development, and marketing of anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions. The companys product portfolio includes a range of innovative solutions for pediatric trauma, deformity correction, scoliosis, and sports medicine, catering to the needs of pediatric orthopedic surgeons and caregivers worldwide.
The companys extensive product line includes notable offerings such as PediLoc, PediPlates, and The Fassier-Duval Telescopic Intramedullary System, which are designed to address specific orthopedic conditions in children. With a strong presence in the pediatric orthopedic market, OrthoPediatrics Corp has established itself as a key player in the industry, with a growing customer base and expanding global reach.
From a technical analysis perspective, the stock has shown a relatively stable trend, with its 20-day and 50-day simple moving averages (SMA20 and SMA50) indicating a potential support level around $21. However, the 200-day simple moving average (SMA200) at $24.19 suggests a longer-term downtrend. The average true range (ATR) of 0.76, equivalent to 3.58%, indicates moderate volatility. Given the current price of $21.37, and considering the
Looking ahead, the companys growth prospects are tied to its ability to innovate and expand its product offerings, as well as its capacity to penetrate new markets. With a market capitalization of $499.10M USD, OrthoPediatrics Corp has a solid foundation to continue investing in research and development, potentially driving future growth. As the company continues to execute on its strategy, investors will be watching for signs of improved profitability and returns on equity.
KIDS Stock Overview
| Market Cap in USD | 483m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 2017-10-12 |
KIDS Stock Ratings
| Growth Rating | -84.0% |
| Fundamental | 26.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -47.8% |
| Analyst Rating | 4.29 of 5 |
KIDS Dividends
Currently no dividends paidKIDS Growth Ratios
| Growth Correlation 3m | -49.7% |
| Growth Correlation 12m | -81.9% |
| Growth Correlation 5y | -87.3% |
| CAGR 5y | -26.43% |
| CAGR/Max DD 3y | -0.40 |
| CAGR/Mean DD 3y | -0.62 |
| Sharpe Ratio 12m | -0.93 |
| Alpha | 0.10 |
| Beta | 0.547 |
| Volatility | 46.32% |
| Current Volume | 291k |
| Average Volume 20d | 143.6k |
| Stop Loss | 18.2 (-5.5%) |
| Signal | -0.59 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-41.8m TTM) > 0 and > 6% of Revenue (6% = 13.2m TTM) |
| FCFTA -0.08 (>2.0%) and ΔFCFTA 2.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 99.23% (prev 88.09%; Δ 11.15pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.06 (>3.0%) and CFO -28.9m > Net Income -41.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (23.3m) change vs 12m ago 0.87% (target <= -2.0% for YES) |
| Gross Margin 71.54% (prev 65.89%; Δ 5.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.25% (prev 40.64%; Δ 6.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.14 (EBITDA TTM -16.7m / Interest Expense TTM 3.96m) >= 6 (WARN >= 3) |
Altman Z'' -1.14
| (A) 0.43 = (Total Current Assets 257.7m - Total Current Liabilities 38.7m) / Total Assets 503.6m |
| (B) -0.50 = Retained Earnings (Balance) -253.3m / Total Assets 503.6m |
| (C) -0.08 = EBIT TTM -36.2m / Avg Total Assets 467.2m |
| (D) -1.74 = Book Value of Equity -258.3m / Total Liabilities 148.1m |
| Total Rating: -1.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.77
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -8.11% = -4.05 |
| 3. FCF Margin -18.72% = -7.02 |
| 4. Debt/Equity 0.27 = 2.46 |
| 5. Debt/Ebitda -5.81 = -2.50 |
| 6. ROIC - WACC (= -15.14)% = -12.50 |
| 7. RoE -11.70% = -1.95 |
| 8. Rev. Trend 93.80% = 7.03 |
| 9. EPS Trend -24.21% = -1.21 |
What is the price of KIDS shares?
Over the past week, the price has changed by -0.21%, over one month by +0.26%, over three months by -5.50% and over the past year by -38.06%.
Is Orthopediatrics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KIDS is around 13.20 USD . This means that KIDS is currently overvalued and has a potential downside of -31.43%.
Is KIDS a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KIDS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.9 | 75.9% |
| Analysts Target Price | 33.9 | 75.9% |
| ValueRay Target Price | 14.5 | -24.6% |
Last update: 2025-09-18 04:37
KIDS Fundamental Data Overview
CCE Cash And Equivalents = 70.1m USD (Cash And Short Term Investments, last quarter)
P/S = 2.1867
P/B = 1.3816
Beta = 1.06
Revenue TTM = 220.7m USD
EBIT TTM = -36.2m USD
EBITDA TTM = -16.7m USD
Long Term Debt = 97.0m USD (from longTermDebt, last quarter)
Short Term Debt = 164.0k USD (from shortTermDebt, last quarter)
Debt = 97.2m USD (Calculated: Short Term 164.0k + Long Term 97.0m)
Net Debt = 52.6m USD (from netDebt column, last quarter)
Enterprise Value = 509.7m USD (482.7m + Debt 97.2m - CCE 70.1m)
Interest Coverage Ratio = -9.14 (Ebit TTM -36.2m / Interest Expense TTM 3.96m)
FCF Yield = -8.11% (FCF TTM -41.3m / Enterprise Value 509.7m)
FCF Margin = -18.72% (FCF TTM -41.3m / Revenue TTM 220.7m)
Net Margin = -18.92% (Net Income TTM -41.8m / Revenue TTM 220.7m)
Gross Margin = 71.54% ((Revenue TTM 220.7m - Cost of Revenue TTM 62.8m) / Revenue TTM)
Tobins Q-Ratio = -1.97 (set to none) (Enterprise Value 509.7m / Book Value Of Equity -258.3m)
Interest Expense / Debt = 1.15% (Interest Expense 1.12m / Debt 97.2m)
Taxrate = 21.0% (US default)
NOPAT = -36.2m (EBIT -36.2m, no tax applied on loss)
Current Ratio = 6.66 (Total Current Assets 257.7m / Total Current Liabilities 38.7m)
Debt / Equity = 0.27 (Debt 97.2m / last Quarter total Stockholder Equity 355.5m)
Debt / EBITDA = -5.81 (Net Debt 52.6m / EBITDA -16.7m)
Debt / FCF = -2.35 (Debt 97.2m / FCF TTM -41.3m)
Total Stockholder Equity = 357.0m (last 4 quarters mean)
RoA = -8.29% (Net Income -41.8m, Total Assets 503.6m )
RoE = -11.70% (Net Income TTM -41.8m / Total Stockholder Equity 357.0m)
RoCE = -7.98% (Ebit -36.2m / (Equity 357.0m + L.T.Debt 97.0m))
RoIC = -8.31% (NOPAT -36.2m / Invested Capital 436.1m)
WACC = 6.84% (E(482.7m)/V(579.8m) * Re(8.03%)) + (D(97.2m)/V(579.8m) * Rd(1.15%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.84%
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -41.3m)
EPS Correlation: -24.21 | EPS CAGR: -4.33% | SUE: 3.02 | # QB: 1
Revenue Correlation: 93.80 | Revenue CAGR: 22.51% | SUE: N/A | # QB: None
Additional Sources for KIDS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle